[2] – 1991 (10/30/1991) – Dr. Dorothy K. Macfarlane letter to Burzynski

This page is linked to:
=====================================
Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/08/critiquing-stanislaw-burzynski-on-the-arrogance-of-ignorance-about-cancer-and-targeted-therapies/
======================================
[2] – 1991 (10/30/1991) – Dorothy K. Macfarlane, M.D., Head, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a one page letter:

Dear Dr. Burzynski:

Enclosed is a copy of the report summarizing our review of the responses seen in 7 brain tumor cases treated by you with Antineoplastons A10 and AS2-1

Dr. Michael Hawkins will be communicating with you at a later date with regard to the question of possibly conducting a confirmatory trial under Division of Cancer Treatment sponsorship

We thank you for your help and cooperation in making these cases available for our review, and for your kind hospitality during our visit

cc: Dr. Michael Hawkins

20130912-192612.jpg

Advertisements